Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead…
cGMP production of 186RNL targeted radiotherapeutic beginning in second half of 2022 to support ongoing and future ReSPECT™ clinical trials AUSTIN, Texas, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a…